Venous Thromboembolism Prophylaxis in Obese Medical Patients: a Retrospective Cohort Study

Yıl 2015, Cilt: 1 Sayı: 4, 104 - 110, 01.10.2015

Duane Bates Lauren Breese Cindy Brocklebank Kelly Zarnke Peter Jamieson Elizabeth Mackay

https://doi.org/10.5455/umj.20151110125822

Öz

Background: The incidence of obesity has increased 3 fold in Canada between 1985 and 2011. Obese patients are 2-3 times more likely to develop venous thromboembolism VTE , and over 60% of VTE occurs in hospital. There is very little literature on VTE prophylaxis in the obese medical patient. Objective s : Our primary objective was to identify the incidence of objectively documented symptomatic VTE during hospitalization or up to ninety days post discharge. Our secondary objectives were to describe the prescribing patterns of VTE prophylaxis received in hospitalized obese medical patients body mass index [BMI] ≥ 30 kg/m2 as well as risk factors for VTE in obese patients. Methods: A retrospective design was used look at obese patients admitted to a general medicine service at three tertiary care academic teaching hospitals in Calgary, AB, Canada from January 1, 2012 to December 31, 2012. VTE was identified based on clinical diagnosis and incidence was calculated. Results: There were 443 patients included in the analysis. The average age and BMI were 58.5 years and 41 kg/m2 respectively, and 70.2% were males. The median length of stay in hospital was 7 days IQR 4-13 . A total of 122 patients 27.5% of patients did not receive thromboprophylaxis during their hospitalization. Unfractionated heparin UFH was the most common agent prescribed 37.9% , and only seven patients received high-dose thromboprophylaxis. The median duration of prophylaxis was 6.5 days IQR 4-12 . Seven patients 1.6% developed VTE 5 pulmonary embolism and 2 DVT during the study period, and six of these patients received thromboprophylaxis. In terms of risk for VTE, the median Padua Prediction Score for the study group was 2 IQR 1-3 . Conclusion: There is very little literature on VTE prophylaxis and incidence of VTE in the obese medical patient. Given the low risk for and incidence of VTE in this study, particularly in the context of 27.5% of the study population not receiving thromboprophylaxis, there is a need for further research to evaluate the efficacy and safety of high dose thromboprophylaxis in the obese medical patient.

Anahtar Kelimeler

Venous thrombosis, thromboprophylaxis, medical patient, obesity

Kaynakça

• 1. Twells LK, Gregory M, Reddigan J, Midodzi WK. Current and predicted prevalence of obesity in Canada: a trend analysis. CMAJ Open. 2014;2:E18-26.
• 2. Whitlock G, Lewington S et al. Body-mass index and causespecific mortality in 900.000 adults: collaborative analyses of 57 prospective studies. Lancet. 2009;373:1083-96.
• 3. Safer Healthcare. Venous Thromboembolism Prevention: Getting Started Kit May 2012 (cited 2015 Jan 30) available from: www.saferhealthcarenow.ca
• 4. Freeman AL, Pendleton RC, Rondina MT. Prevention of venous thromboembolism in obesity. Expert Rev Cardiovasc Ther. 2010;8:1711-21.
• 5. Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage B. Efficacy and safety of high-dose prophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111:88-93.
• 6. Mahan CE, Spyropoulos AC. ASHP therapeutic position statement on the role of pharmacotherapy in preventing venous thromboembolism in hospitalized patients. Am J Health-System Pharm. 2012;69:2174-90.
• 7. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis 9th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines. Chest. 2012;141;e195S-e226S.
• 8. Leizorovicz A, Cohen AT, Turpie AGG, Olsson CG, Vaitkus PT, Goldhaber SZ. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110:874-9.
• 9. Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med.1999;341:793-80.
• 10. Cohen T, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W et al. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomized placebo controlled trial. Br Med J. 2006;332:325-29.
• 11. Nutescu EA, Spinler SA, Wittlowsky.Low-molecular weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother. 2009;43):1064-83.
• 12. Barbar S, Noventa F, Rossetto V, Ferrari A, Brandolin B, Perlati M et al. A risk assessment model for the identification of hospitalized medical patients at risk for venous thrombo embolism: the Padua Prediction Score. J Thromb Haemost. 2010;8:2450-57.
• 13. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-94.
• 14. Linkins LA ,Dans AL Moores LK , Bona R, Davidson BL, Schulman S, Crowther M. Treatment and prevention of heparin induced thrombocytopenia. Antithrombotic therapy and prevention of thrombosis, 9th ed American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141;e495S-e530S.
• 15. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification 2002. New York (NY): National Kidney Foundation. [cited 2015 May 21]. Available from http://www2.kidney.org/professionals/ KDOQI/guidelines
• 16. Alikhan R, Cohen AT, Combe S, Samama MM, Desjardins L, Eldor A et al. Prevention of venous thromboembolism in medical patients with enoxaparin: a subgroup analysis of the MEDENOX study. Blood Coagul Fibrinolysis 2003;14:341-346.
• 17. Kucher N, Leizorovicz A, Vaitkus PT, Cohen AT, Turpie AGG et al. Efficacy and safety of fixed low dose dalteparin in preventing venous thromboembolism among obese or elderly hospitalized patients. Arch Intern Med. 2005;165:341-45.
• 18. Wang TF, Milligan PE, Wong CA, Deal EN, Thoelke MS, Gage BF. Efficacy and safety of high-dose thromboprophylaxis in morbidly obese inpatients. Thromb Haemost. 2014;111:88-93.
• 19. Flanders SA, Greene T, Grant P, Kaatz S, et al. Hospital performance for pharmacological venous thromboembolism prophyalxis and rate of venous thromboembolism a cohort study, JAMA Intern Med 2015;174:1577-84.
• 20. Caprini JA. Thrombosis risk assessment as guide to quality patient care. Dis Mon. 2005;51:70-8.
• 21. Lederle FA, Zylla D, MacDonald R, Wilt TJ. Venous thromboembolism prophyalxis in hospitalized medical patients and those with stroke: a background review for an American College of Physicians Clinical Practice Guideline. Ann Intern Med 2011;155:602-15.